logo-loader

Scancell to raise up to £8mln to develop its three main drug candidates

Published: 23:18 18 Apr 2018 AEST

Cliff Holloway, chief executive at Scancell Holdings Plc (LONSCLP), tells Proactive Investors they're raising up to £8mln through a placing and open offer – cash that will be used develop their three main drug candidates.

A placing and subscription at 12 pence a share will account for £6mln of the total.

The company also wants to include existing investors, so is planning a £2mln open offer of stock once the placing has been concluded.

New Scancell chief sets out his vision to commercialise groundbreaking...

Cliff Holloway, chief executive of Scancell Holdings Plc (LON:SCLP), spoke to Proactive soon after taking over as CEO at the immuno-oncology company. Holloway says generating clinical data's a big focus for them in the near-term. ''Over the next two years we expect to see clinical...

on 15/2/18